In this respect an understanding of the restorative function of deep slow-wave sleep should not be underestimated.

Nocturia can be divided into three main causes: Nocturnal Polyuria - overproduction of urine at. Those interventions which increase the time before the first wake to void in an individual with several episodes of nocturia should be deemed of greater clinical significance than those that simply reduce the total number of voided episodes. Your treatment for nocturia will depend on the cause. The management of nocturia needs to address not only the underlying medical conditions, but also the impact of nocturnal polyuria вЂ“ the latter through anti-diuretic pharmacology or by manipulating the timing of an individualвЂ™s diuresis to avoid periods of sleep. This happens because their bodies are retaining fluid throughout the day. Nocturia is increasingly recognized as a surrogate marker for poor health and one that carries with it an increased risk of mortality. While Polyuria causes frequent urination through day and night, in women with Nocturnal Polyuria, a normal quantity of urine is formed in the day, while excessive quantity is formed in the night, leading to nocturnal urination. Its association with multiple medical comorbidities and nocturnal polyuria explains the generally poor response to interventions aimed at improving outflow obstruction or lessening the impact of bladder instability. The prevalence of nocturnal polyuria increased with age, particularly among those with overactive bladder. patients, men and women, 18 years and older, with an average of 2 nocturnal voids per night evidence for nocturnal polyuria (nocturnal urine volume >33 of total volume over 24h), determined on frequency/volume chart Diuresis <2. It is seldom the result of obstructive lower urinary tract symptoms alone. The prevalence of nocturia of two or more voids among respondents was 33, and, among these, 32 of men and 39 of women had nocturnal polyuria as defined by >33 of 24-hour urine output production overnight. Patients have to fill out a frequency/volume chart during the first 14 days.Nocturia is a poorly understood symptom complex.On day 3 the patient has to give a urine sample.If the patient is at high risk for side effects, blood has to be taken during the first 7 days. These first 2 visits (day 3 and day 7) are standard procedure.

On day 3 and day 7 a blood sample will be taken at the UZ Ghent for safety control (Na+, K+, creatinin, osmolality = good clinical practice guideline).The study starts when the patients takes his first prescribed Minirin Melt tablet: This group already went through the evaluation phase (by participation to study 1 or study 3 as mentioned above) and they have been prescribed Minirin Melt 60 Вµg ambulatory. The study starts when the 1st Minirin Melt tablet has been taken (= day 1). This procedure is not a part of this study. Patients that still have to undergo an evaluation phase, according to standard procedures (e.g. Nocturnal polyuria (NP), an etiology of nocturia, has been defined in multiple ways, including age-related nocturnal polyuria index >.33 in older patients. During 30 days, the patient has to take Minirin Melt 60Вµg in the evening before going to bed. The participants must have a nocturnal frequency of 2 and the first uninterrupted sleep period (FUSP) must occur within < 2.5 h. Nocturnal polyuria exists when the nocturnal urine volume represents >20 of the 24 hour.

The patient will be given a prescription to buy Minirin Melt 60Вµg at the local pharmacy. A total of 20 male patients, 65 years old, with nocturnal polyuria, defined as a nocturnal polyuria index (NPi) (nocturnal urine volume / 24 h urine volume) value 0.33, will participate in this study. Aims Nocturnal polyuria syndrome (NPS) denotes nocturnal polyuria (NP) in the absence of identifiable contributory factors. Nocturnal polyuria (NP) is increased urine production at night.

Can the investigators individualize treatment and reduce risk for hyponatraemia? Nocturnal Polyuria: Its All About Definition, and Be Patient Stephan Madersbacher a, Jean-Nicolas Cornu b a Department of Urology, Donauspital, Vienna.

Can the investigators identify patients who are likely to develop hyponatraemia?.

Are differences related to the pathophysiological factors involved in nocturia?.

The main questions the investigators want to answer are: The objective of this study is to find out what the pharmacodynamic (PD) characteristics of desmopressin melt are in nocturia patients (compared to healthy volunteers and children).

Why Should I Register and Submit Results?.